References
- Centers for Medicare & Medicaid Services [Internet]. National coverage determination for positron emission tomography (PET) scans (220.6). Available from: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId = 211&ncdver = 4&NCAId = 92&ver = 19&NcaName = Positron+ Emission+ Tomography+&bc = BEAAAAAAIAAA&
- Smith-Bindman R, Miglioretti DL, Johnson E, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010. JAMA 2012;307:2400–2409.
- Chee KG, Nguyen DV, Brown M, et al. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 2008;168: 1541–1549.
- Misono S, Rue T, Rajendran J, et al. Effects of upstaging from PET scan on survival in head and neck squamous cell carcinoma. Head Neck 2010;32:1283–1287.
- Risum S, Hogdall C, Loft A, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? Gyn Oncol 2010;116:395–398.
- Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998–2003. J Clin Oncol 2012;30:2725–2730.
- National Cancer Data Base [Internet]. Available from: http://www.facs.org/cancer/ncdb/
- US Food and Drug Administration [Internet]. Available from: http://www.fda.gov/default.htm
- Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019–5026.
- Flowers CR, Fedewa SA, Chen AY, et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 2012;21: 1520–1530.
- Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
- Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507–3516.
- Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013;122: 61–67.
- Centers for Medicare & Medicaid Services [Internet]. National coverage determination for stem cell transplantation (110.8.1). Available from: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId = 45&ncdver = 5&NCAId = 10&ver = 8&NcaName = Autologous+ Stem+ Cell+ Transplantation+(AuSCT)+ for+ Multiple+ Myeloma&bc = ACAAAAAAIAAA&
- Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
- Hofman MS, Ball DL, Mac Manus MP. Let's get SEERious: more accurate staging with consequent high management impact is not just stage migration. J Clin Oncol 2013;31:819.
- Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol 2013;24: 1352–1359.